Ph.D. in Cellular & Clinical Neurobiology from Wayne State University School of Medicine. Associate Professor of Psychology at Minnesota State University, Mankato.
Dr Bagley is a Associate Professor in the Discipline of Pharmacology at the University of Sydney.
A/Prof Bagley completed a PhD at the University of Sydney in 2001. She was a C.J Martin Fellow from 2001 to 2006. During this time she was a postdoctoral fellow in the laboratory of Professor Gary Westbrook at the Vollum Institute (Oregon, USA) and at the Pain Management Research Institute (University of Sydney).
Dr Bagley began developing her research laboratory at the Brain and Mind Institute (2010-2011) and then moved to Pharmacology in 2011.
--- CURRENT POSITION ---
CEO of neurochlore and B ATherapeutics
--- EDUCATION ---
° 1973-1979 - Post-doctoral & sabbatical studies: University of Cambridge (UK), University of Oslo (Norway) and McGill University (Canada)
° 1971 - Doctorat ès-sciences, Université de Paris VI (France)
° 1966 - B Sc. Biochemistry-Physiology, Hebrew University of Jerusalem (Israel)
--- AWARDS ---
° 2014 - Finalist Créa13 -Neurochlore
° 2013 - Award « Tremplins de La Provence » - Neurochlore
° 2012 - Award of the of the FNRS ( Fonds de la Recherche Scientifique de Belgique) of Belgium
° 2010 - Award of the European Society of Epilepsy
° 2009 - Award of the Grand Prix de la Recherche médicale de l'INSERM
° 2009 - Docteur Honoris causae, Liège University (Belgium)
° 2006 - Rotary Brain Research Award
° 2002 - The Health Price (Grand Prix de la Santé) of the Foundation of French Electricity ° 2000 - The American Epilepsy Society Research Award for outstanding research in epilepsies
Dr. Glen Borchert holds joint appointments as an Assistant Professor in Biology and Pharmacology at the University of South Alabama. He originally received a B.S. in Biology from the University of Tennessee then completed a Ph.D. in Genetics from the University of Iowa. Dr. Borchert’s research focuses largely on identifying novel genetic regulators and defining their roles in oncogenesis, microbiology and speciation. Since starting his laboratory at South Alabama in August 2012, Dr. Borchert has published dozens of papers in peer reviewed journals and had numerous grant applications funded including a highly prestigious NSF CAREER award (2014-2019).
Dr. Vincenzo Brancaleone is Assistant Professor of Pharmacology, Department of Science, University of Basilicata.
Dr. Brancaleone main research field includes:
1) vascular biology in vivo and in vitro in physiopathological conditions related to gaseous mediators: role of nitric oxide (NO) and hydrogen sulfide (H2S);
2) role of sphingosine-1-kinase/sphingosine-1-phosphate (S1PK/S1P) pathway in vascular, respiratory and inflammatory processes;
3) role of Annexin A1 and its receptor (Formylated Peptide Receptor 2, FPR2) in resolving mechanism in inflammation.
Dr. Brancaleone is full member of British Pharmacological Society (BPS) and Italian Society of Pharmacology (SIF).
He performs reviewer activity for international relevant and impacted scientific journal: Mediators of Inflammation (IF:3.263), British Journal of Pharmacology (IF:4.409), Inflammation Research (IF:2.109), Diabetes & Vascular Disease Research (IF:2.116), FasebJ (IF:5.299)
Minjun Chen is a principal investigator working at the Division of Bioinformatics and Biostatics of the US FDA’s National Center for Toxicological Research and serve as the adjunct faculty and mentor for the bioinformatics program joint by Univ. of Arkansas at Little Rock (UALR) and Univ. of Arkansas for Medical Sciences (UAMS). Currently, he co-chairs the FDA Liver Toxicity Working Group since 2014 and is the editor of the Springer book titled “Drug-induced Liver Toxicity”. His primary research interests encompass drug-induced liver injury, drug safety, bioinformatics, and personalized medicine. He has authored or co-authored more than 80 scientific publications and book chapters.
Chair and Professor, Pharmacology and Eric L. and Lila D. Nelson Chair in Neuropharmacology, School of Medicine, University of California, Irvine.
Professor of Pharmacology in the Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University. I study the cellular basis of opioid and cannabinoid receptor/ligand actions, with with the aim of better understanding their acute effects and the adaptations that occur after prolonged administration. This work has taken me to the University of Washington, University of Bristol, University of Sydney and the Vollum Institute before arriving at Macquarie. At the moment my lab focuses on the pharmacology of illicit synthetic cannabinoids and the molecular effects of phytocannabinoids.
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Dr. Costa-Lotufo is a full professor at the Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo. Her lab is focused on the discovery of new anticancer compounds from Brazilian marine biodiversity and studies on their mechanisms of action. She coordinate a multidisciplinary project to access marine microorganisms diversity and biotechnological potential along the Brazilian coast and islands. Dr. Costa-Lotufo’s activities include the supervision of undergraduate and graduate students and post-doctoral fellows. She has published book chapters, review articles and more than 230 articles in peer-reviewed journals. On 2010, Dr. Costa-Lotufo was nominated as a young scientist of the Brazilian Academy of Science (2010-2014).
BSc, PhD. Head of School of Food Science and Environmental Health at Dublin Institute of Technology. Worked in translational research developing an immunotherapy for brain cancer for five years. Main focus: cancer; new therapeutic technologies; nanoscience; cold atmospheric plasma; gene therapy; immunotherapy - resulting in Phase I clinical trials and publications. James leads a multidisciplinary research team applying novel technologies for the treatment of brain cancer.